Study of NHWD-870 for advanced NUT cancer
Part of Cancer clinical trials.
This trial tests a new drug called NHWD-870 for people with NUT cancer (a rare cancer linked to a gene change). The goal is to see if the drug can help shrink tumors or slow the cancer's growth.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You must be 12 to 75 years old.
- You must have been diagnosed with NUT cancer (confirmed by a tumor biopsy or special lab tests).
- You must be well enough to be up and about for at least half the day (ECOG score 0-2).
- You must not have had treatment with another BET inhibitor drug before.
- You must not have other cancers (except treated skin cancer or cervical cancer in situ) in the last 3 years.
- You must not have active bleeding or a high risk of bleeding from the tumor.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial offers early access to an experimental drug called NHWD-870 for people with advanced solid tumors or lymphomas that have a specific genetic change called a NUT rearrangement. The goal is to see if this drug can help shrink or slow the growth of these cancers.
This trial studies a new drug called HW071021 for people with advanced solid tumors that have stopped responding to standard treatments. It aims to see if the drug can help shrink or control the cancer.
This study tests a new experimental drug (NWY001) for people with advanced solid tumors that have stopped responding to standard treatments. It is a phase 1 trial, meaning it is early research to find the right dose and check for side effects.
This trial tests a new investigational drug (JNJ-87890387) for people with certain advanced solid tumors that have spread or cannot be removed by surgery. It aims to see if the drug is safe and effective.
This trial tests a new drug called XNW29016 for people with advanced cancer that has stopped responding to standard treatments. It aims to see if the drug can shrink tumors or slow their growth.
This early-phase trial tests a new oral targeted drug, ND-003, for people with advanced solid tumors that have not responded to standard therapy. The study focuses on tumors with specific gene changes (NTRK or RET fusions), especially in the second part, to see if the drug can shrink tumors and be safe.
Hear when a new Advanced Solid Tumor (Phase 1) trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.